Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2014

View Archived Issues

Researchers present novel radiomitigating compounds

Nuvilex forms consortium to oversee development of treatment for type 1 diabetes

Janssen and Transposagen to collaborate on allogeneic CAR T-cell therapies

Thermo Fisher Scientific and Samsung Electronics initiate POC diagnostic collaboration

Santhera and PPMD collaborate on risk/benefit analysis of idebenone as DMD respiratory therapy

Sevion enters into chimerasome research agreement with Avidity NanoMedicines

ACC inhibitors reported in Nimbus Discovery patent

First in vitro and in vivo data for DNA-PK and mTOR kinase dual inhibitor CC-115

Human tolerability and new preclinical data presented for ShK-186

PEGylated H-NOX protein may enhance radiotherapy for glioblastoma

Recombinant human placental growth factor as promising therapy for artherosclerosis

Project targeting CD73 supported by AmorChem and Univalor

Phase I results presented for AZD-7451 in adults with recurrent glioblastoma multiforme

Tonix Pharmaceuticals initiates ascending-dose phase I trial of oral TNX-201

FDA accepts for review Dysport sBLA for upper limb spasticity

Lilly patent describes prostanoid EP4 receptor antagonists

EZH2 inhibitors prepared and tested at GlaxoSmithKline

Novartis starts recruitment of patients with Sjogren's syndrome for phase II trial of CFZ-533

Takeda synthesizes PKC theta inhibitors

Chinese team divulges HGFR/VEGFR inhibitors for cancer

Kyowa Hakko Kirin to launch pegfilgrastim in Japan

Novartis applies for approval of vildagliptin/metformin combination tablets in Japan

First-in-human data for the anti-IL-13 antibody RPC-4046

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...